Evolving Landscape of Multiple Myeloma: Current and Emerging Therapies for Frontline and Early Relapse

Medical experts explore the current standard of care and evolving treatment landscape for transplant eligible multiple myeloma, a complex hematological malignancy.

Multiple myeloma specialists analyze recent findings presented at EHA 2024, offering expert perspectives on the PERSEUS and IsKIA clinical trials and their implications for patient care.

Key opinion leaders evaluate the clinical implications of updated data presented at EHA 2024, interpreting how these findings may influence future treatment strategies in multiple myeloma.

Multiple myeloma experts analyze recent developments in transplant-ineligible newly diagnosed multiple myeloma treatment, focusing on the latest updates presented at EHA 2024 and their potential impact on patient care.

A panel of experts examines the impact and potential of CAR T-cell therapy in earlier treatment lines for multiple myeloma, evaluating its efficacy, safety.

Experts provide concluding insights on CAR-T cell therapy and offer their perspectives on the evolving treatment landscape for multiple myeloma, highlighting potential future directions and innovations in patient care.